Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) EBT (2021 - 2025)

Historic EBT for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to -$2.0 million.

  • InMed Pharmaceuticals' EBT rose 2123.48% to -$2.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$7.7 million, marking a year-over-year increase of 306.04%. This contributed to the annual value of -$8.2 million for FY2025, which is 643.78% down from last year.
  • InMed Pharmaceuticals' EBT amounted to -$2.0 million in Q4 2025, which was up 2123.48% from -$1.7 million recorded in Q3 2025.
  • Over the past 5 years, InMed Pharmaceuticals' EBT peaked at -$336591.0 during Q2 2023, and registered a low of -$7.9 million during Q2 2022.
  • For the 5-year period, InMed Pharmaceuticals' EBT averaged around -$2.6 million, with its median value being -$2.1 million (2022).
  • In the last 5 years, InMed Pharmaceuticals' EBT surged by 9572.31% in 2023 and then plummeted by 47356.58% in 2024.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' EBT stood at -$4.3 million in 2021, then skyrocketed by 51.01% to -$2.1 million in 2022, then grew by 29.55% to -$1.5 million in 2023, then plummeted by 74.2% to -$2.6 million in 2024, then grew by 21.23% to -$2.0 million in 2025.
  • Its EBT was -$2.0 million in Q4 2025, compared to -$1.7 million in Q3 2025 and -$1.8 million in Q2 2025.